[Market Feature] Hans Biomed Shares Rise on Product Diversification and Improved Financial Structure

Hans Biomed's stock price is showing a strong increase of over 14%, driven by factors such as product diversification and improvements in its financial structure.

As of 11:43 a.m. on February 2, Hans Biomed shares were trading at 45,250 won, up 14.56% (5,750 won) from the previous trading day.

On this day, SangSangin Securities issued a "Buy" investment opinion on Hans Biomed and set a target price of 50,000 won. Ha Taegi, a researcher at SangSangin Securities, stated, "Hans Biomed's sales and profits are expected to see full-fledged growth next year," adding, "Although there may be a short-term correction due to the recent sharp rise in the stock price, the long-term upward trend is likely to continue, reflecting the company's potential growth value."

He also noted, "Since October last year, sales of the ECM-based skin booster Cellrdiem have grown rapidly. With the re-launch of the Bounce breast implant scheduled for March-April this year and entry into the Chinese bone graft market, overall company sales are expected to increase significantly."

There are also signs that the company's financial structure is improving. Researcher Ha explained, "Although the company paid approximately 23 billion won in damages in a civil lawsuit in the second half of last year, it resolved this with 10 billion won in existing funds, 17 billion won raised through the sale of treasury shares, and 18.6 billion won from a paid-in capital increase. The company is believed to have about 20 billion won in cash-equivalent assets, and its 35.3 billion won in short-term borrowings is secured by the company's headquarters building, which is currently valued at over 100 billion won, so there should be no major issues."